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The nucleoprotein (NP) of influenza B virus is 50 amino acids longer at the N-terminus than influenza A
virus NP and lacks homology to the A virus protein over the first 69 residues. We have deleted the N-terminal
51 and 69 residues of the influenza B/Ann Arbor/1/66 virus NP and show that nuclear accumulation of the
protein is unaffected. This indicates that the nuclear localization signal is not located at the extreme N
terminus, as in influenza A virus NP. To determine if the N-terminal mutants could support the expression and
replication of a model influenza B virus RNA, the genes encoding the subunits of the viral RNA-dependent RNA
polymerase (PA, PB1, and PB2) were cloned. Coexpression of NP and the P proteins in 293 cells was found to
permit the expression and replication of a transfected model RNA based on segment 4 of B/Maryland/59, in
which the hemagglutinin-coding region was replaced by a chloramphenicol acetyltransferase gene. The ex-
pression and replication of the synthetic RNA were not affected by the replacement of NP with NP mutants
lacking the N-terminal 51 or 69 residues, indicating that the N-terminal extension is not required for
transcription or replication of the viral RNA. In addition, we report that the influenza B virus NP cannot be
functionally replaced by type A virus NP in this system.
Influenza A and B viruses have segmented genomes, each
comprising eight negative-strand RNAs. The virion RNAs are
complexed with nucleoprotein (NP) and subunits of the RNA-
dependent RNA polymerase (PA, PB1, and PB2) to form viral
ribonucleoproteins (vRNPs) (18). After the entry and uncoat-
ing of the virus, vRNPs enter the cell nucleus, where transcrip-
tion and replication of the viral RNA takes place. The NP
facilitates the nuclear import of vRNPs by interacting with
proteins belonging to the karyopherin a family of nuclear
transport factors (NPI-1 and NPI-3) (27–29). In addition, the
NP of influenza A virus has been implicated in the determina-
tion of host range (32), the initiation of viral mRNA synthesis
(3), RNA elongation (11), and the switch between mRNA and
cRNA synthesis (antitermination) (5).
The region of the influenza A virus NP responsible for RNA
binding has been mapped to the N-terminal third of the pro-
tein, specifically between residues 1 and 77 and 79 and 180 (1,
17). Recently, it was reported that the N terminus of influenza
A virus NP also contains a nonconventional nuclear localiza-
tion signal (NLS) (25, 34). Significantly, influenza B virus NP
lacks homology to the A virus protein at the N terminus. For
all influenza B virus isolates for which the sequences are avail-
able (7, 9, 13, 20, 31), the NP is 50 amino acids longer at the N
terminus than the A virus protein, and indeed lacks homology
to influenza A virus NP over the first 69 residues (Fig. 1). The
length and amino acid sequence of the N-terminal extension
are highly conserved among influenza B virus NPs, implying
that it may have a conserved function.
Recently, the amino acid residues in influenza A virus NP
that interact with nuclear transport factors NPI-1 and NPI-3
were identified (34). The NPI-1 and NPI-3 binding motifs are
located in the N-terminal 13 residues of influenza A virus NP
(Fig. 1) but are absent from this position in the type B virus NP
and are not found elsewhere in the protein. The NP of influ-
enza B virus also lacks classical mono- and bipartite NLSs such
as those described for the large T antigen of simian virus 40
and nucleoplasmin, respectively (26). It is therefore of interest
to investigate the function of the conserved N-terminal exten-
sion of influenza B virus NP, and in particular to determine if
this region contains an NLS.
Cloning of the influenza B/AA/1/66 virus NP gene. To assess
the role of the N-terminal residues of influenza B virus NP, the
cDNA for the B/AA/1/66 NP gene was amplified by reverse
transcription-PCR (RT-PCR) with primers based on the pub-
lished sequence (9). Influenza B/AA/1/66 virus was grown at
34°C in 10-day-old embryonated chicken eggs and purified
from the allantoic fluid 48 h postinfection by centrifugation
through a 30% sucrose cushion. The virus was resuspended in
TMK (10 mM Tris-HCl [pH 7.4], 1.5 mM MgCl2, 10 mM KCl),
lysed by the addition of sodium dodecyl sulfate to 0.3%, and
then digested with 2 U of proteinase K (GIBCO/BRL) for 10
min at 56°C. The viral RNA was then purified by phenol
extraction and precipitated with ethanol. Approximately 200
ng of viral RNA was used for reverse transcription with 100 ng
of an oligonucleotide (NPstart; 59 gcgcgcaagcttATCAAAAT
GTCCAACATG 39) annealing to residues 53 to 70 of the
segment 5 RNA which encodes the NP (numbering for all
oligonucleotides listed here is of the positive-sense RNA).
Reverse transcription was performed with a 20-ml reaction
mixture containing 50 mM Tris-HCl (pH 8.3), 50 mM KCl, 10
mM MgCl2, 10 mM dithiothreitol, the four dNTPs (1 mM
each), 30 U of human placental RNase inhibitor (Pharmacia),
and 5 U of avian myeloblastosis virus reverse transcriptase
(GIBCO/BRL). The product was amplified by PCR with
NPstart and an oligonucleotide (NPstop; 59 gcgcgcgtcgacGTT
GCTTTAATAATCGAG 39) annealing to residues 1730 to
1747 with Vent DNA polymerase (New England Biolabs). The
NP gene was then cloned on a HindIII-SalI fragment into
mammalian expression vector pcDNA3 (Invitrogen) under the
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control of the human cytomegalovirus immediate-early pro-
moter/enhancer, generating plasmid pcDNA3-NP.
Next, we made deletions which removed the N-terminal
extension (NPD51) and all of the nonhomologous sequence at
the N terminus (NPD69) (Fig. 1). The NPD51 mutant lacks
amino acid residues 2 to 51 and was generated by PCR with
oligonucleotide 59 gcgcgcaagcttATCAAAATGGAAAGGGC
AACCACAAGC 39 and NPstop, with pcDNA3-NP as the tem-
plate. The product was cloned into pcDNA3 as described for
NP, giving pcDNA3-NPD51. Mutant NPD69 lacks amino acids
2 to 69 and was generated with oligonucleotide 59 gcgcgcaagct-
tATCAAAATGCAAACCCCGACAGAG 39 and NPstop, giv-
ing pcDNA3-NPD69. We also deleted further into the protein
(residues 2 to 82) by PCR with oligonucleotide 59 gcgcgcaagct-
tATCAAAATGGTAGTGAAACTGGGT 39 and NPstop, giv-
ing pcDNA3-NPD82. Proteins of the expected size were syn-
thesized in in vitro translation reactions with T7 run-off
transcripts from SmaI-linearized pcDNA3-NP, pcDNA3-
NPD51, pcDNA3-NPD69, and pcDNA3-NPD82 (Fig. 2A).
N-terminal deletions in influenza B virus NP do not affect
nuclear accumulation. Plasmids for the expression of NP,
NPD51, NPD69, and NPD82 were transfected into MDCK
cells, and the proteins were visualized by indirect immunoflu-
orescence with a mouse anti-B virus NP monoclonal antibody
(MAb) and an anti-mouse immunoglobulin G-fluorescein iso-
thiocyanate conjugate. We were unable to detect NPD82 with
either of two different anti-B virus NP MAbs (data not shown),
which may indicate that the protein is unstable when expressed
in mammalian cells. In cells fixed 24 h posttransfection, NP,
NPD51, and NPD69 were found to accumulate mostly in the
nucleus (Fig. 3). However, in cells fixed 48 h posttransfection
NP, NPD51, and NPD69 were distributed mostly in the cytosol.
This pattern was also observed upon transfection of plasmid
pHMG-NP, which contains the influenza A/PR/8/34 virus NP
gene under the control of a mouse hydroxymethylglutaryl-
coenzyme A reductase promoter (kindly supplied by J. Pav-
lovic, University of Zu¨rich, Zu¨rich, Switzerland) (Fig. 3), and is
consistent with observations that NP expressed in the absence
of other virus proteins is capable of shuttling between the
nucleus and cytosol (25, 35).
Our data indicate that the N-terminal extension of influenza
B virus NP does not contain the sole NLS. The region of the
influenza A virus NP responsible for nuclear accumulation has
been mapped by Wang et al. (34) to residues 1 to 13 and
separately by Neumann et al. (25) to residues 1 to 38. In both
cases, the N-terminal residues have been shown to possess
NLS activity, since they can target a normally cytoplasmic
protein to the nucleus (25, 34). However, the authors of both
reports concede that mutants lacking part or all of the NLS still
enter the nucleus, indicating that other, perhaps weaker, NLSs
exist in the protein.
Earlier results with influenza A virus NP had suggested that
a motif which determines the accumulation of NP in the nuclei
of Xenopus oocytes was located between residues 327 and 345
(8). This region is conserved in the NP of influenza B/AA/1/66
virus; however, its importance in determining the nuclear ac-
cumulation of type A virus NPs in mammalian cells is con-
tested (25, 34). The identification of the sequence(s) respon-
sible for the nuclear accumulation of the influenza B virus NP
awaits further mutagenesis of the protein.
A plasmid-based system to study the expression and repli-
cation of influenza B virus RNAs. A number of systems to
study the expression and replication of influenza virus RNAs
have been described. Luytjes et al. (21) first reported that RNP
complexes reconstituted in vitro with purified NP and P pro-
teins and a synthetic influenza virus RNA containing a cat gene
could give rise to CAT activity following transfection into
helper virus-infected cells. It has since been shown that func-
tional RNP complexes can be reconstituted in vivo, since cells
which supply NP and the P proteins in trans from plasmids,
vaccinia virus, or simian virus 40 recombinants, can support the
expression and replication of a transfected model influenza A
virus RNA (6, 10, 12, 15, 22, 38). To establish such a system for
FIG. 1. Alignment of the amino acid sequences of the influenza A/PR/8/34 and B/AA/1/66 virus NPs at the N-termini. The alignment was generated with the FASTA
program (Genetics Computer Group, University of Wisconsin) and predicts 37.7% identity and 76.2% similarity of the proteins in a 496-amino-acid overlap. The
residues in influenza A/PR/8/34 virus NP reported by Wang et al. (34) to interact with NPI-1 and NPI-3 are shown in boldface below the influenza A virus sequence.
Neumann et al. (25) have separately reported that residues Lys7 and Arg8 are crucial for nuclear import of the A/WSN/33 NP. Arrows indicate the extent of the
N-terminal deletions in the type B virus NP made in this study, vertical lines denote amino acid identity, and colons refer to conservative changes.
FIG. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) of the influenza B/AA/1/66 virus NP and NP deletion mutants (A) and
of influenza B/AA/1/66 virus polymerase proteins (B) synthesized in vitro. Rabbit
reticulocyte lysates (Promega) were primed with 50 ng of T7 transcripts from
SmaI-linearized templates in the presence of [35S]methionine according to the
manufacturer’s instructions. Proteins were resolved on an SDS–10% PAGE gel
and visualized by autoradiography. Numbers refer to the sizes in kilodaltons of
protein standards.
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FIG. 3. Localization of NP and NP deletion mutants in MDCK cells. MDCK cells (American Type Culture Collection; CCL 34) were grown on glass coverslips to
50 to 70% confluency and were transfected with 5 mg of pcDNA3-NP, pcDNA3-NPD51, pcDNA3-NPD69, or pHMG-NP (encoding A/PR/8/34 NP), by using 30 mg of
Pfx-2 lipofection reagent (Invitrogen) in serum-free Eagle’s minimal essential medium. Twenty-four or forty-eight hours after transfection the cells were fixed and
permeabilized with 220°C absolute ethanol for 5 min and then analyzed by indirect immunofluorescence with a mouse anti-B virus NP MAb (MAS774b; Harlan
Sera-lab) and an anti-mouse immunoglobulin G-fluorescein isothiocyanate conjugate. Samples were mounted with Mowiol 40-88 and 1,4-diazabicyclo[2.2.2]octane
(Aldrich) and analyzed with a Zeiss Axiovert 135 fluorescence microscope and a 1003 oil immersion lens. The same localization of NP or the NP deletion mutants
was observed if the cells were fixed with 3% (wt/vol) paraformaldehyde and permeabilized with 0.1% (vol/vol) Triton X-100 (data not shown).
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influenza B virus, the genes encoding PA, PB1, and PB2 were
cloned from B/AA/1/66 into pcDNA3.
The PA gene was amplified by reverse transcription from
B/AA/1/66 viral RNA and PCR with oligonucleotides PAstart
(59 gcgcgcgaattcGCCATAATGGATACTTTT 39) and PAstop
(59 gcgcgcgtcgacCTTCTTTCATTCATCCAT 39), which an-
neal to residues 24 to 41 and 2199 to 2116, respectively. The
PB1 gene was amplified with oligonucleotides PB1start (59
gcgcgcgaattcTTTAAGATGAATATAAATCC 39) and PB1
stop (59 gcgcgcgtcgacCGAAGCTTATATGTGCCC 39), which
anneal to residues 16 to 35 and 2269 to 2286, respectively. Both
the PA and PB1 RT-PCR products were cloned on EcoRI-SalI
fragments into pcDNA3. We were unable to amplify the full-
length PB2 gene from B/AA/1/66 viral RNA by RT-PCR;
therefore, the gene was cloned in two halves, by making use of
primers PB2start (59 gcgcgcgaattcTTCAAGATGACATTGG
CC 39 [anneals to residues 18 to 35]) and PB26 (59 gcgcgc-
GAAtTCCTCTTCTCCG 39 [1103 to 1118]) and primers PB27
(59 gcgcgcGAaTTCCATGTAAGATG 39 [1113 to 1129]) and
PB2stop (59 gcgcgcgtcgacTTTATATTAGCTCAAGGC 39
[2324 to 2342]). Oligonucleotides PB26 and PB27 introduce a
silent change (G3A at position 1115) to generate an EcoRI
site. The product of RT-PCR with PB2start and PB26 was first
cloned into the EcoRI site of pcDNA3, and then the PB27 and
PB2stop RT-PCR product was cloned into this plasmid on an
EcoRI-SalI fragment.
To confirm that the cloned cDNAs for the B/AA/1/66 NP
and P genes encode proteins of the expected size, in vitro
translation reactions were performed with T7 transcripts from
SmaI-linearized pcDNA3-NP, pcDNA3-PA, pcDNA3-PB1,
and pcDNA3-PB2. With the exception of PB2, the electro-
phoretic mobilities of the proteins correlated with their pre-
dicted molecular weights (Fig. 2B). The PB2 protein migrated
at a rate below that expected on the basis of its predicted
molecular weight; however, this has also been noted for the
PB2 protein of B/Panama´/45/90 (13). Proteins corresponding
in size to the influenza B/AA/1/66 virus NP and P proteins were
identified in a preparation of purified radiolabeled B/AA/1/66
virus (data not shown).
To test the activities of the cloned NP and P proteins, plas-
mids pcDNA3-NP, pcDNA3-PA, pcDNA3-PB1, and pcDNA3-
PB2 were cotransfected into 293 cells and the cells were trans-
fected at intervals thereafter with a synthetic influenza B virus
RNA (HABCAT). The HABCAT RNA is based on segment 4
of B/Md/59 and contains a negative-sense cat gene in place of
the hemagglutinin coding region (4). We observed that chlor-
amphenicol acetyltransferase (CAT) activity could be detected
if the cells were transfected with the plasmids and the RNA at
the same time, but not if the RNA was added three or more
hours after the plasmids (Fig. 4). The ability to detect CAT
indicates that the transfected RNA was reconstituted intracel-
lularly into functional RNPs capable of synthesizing mRNA.
The level of CAT activity obtained on transfection of the
HABCAT RNA into cells supplying NP and the P proteins in
trans was comparable to the levels achieved on transfection of
the naked RNA into helper virus-infected cells (data not
shown). The amounts of the model RNA and plasmids for the
expression of NP and P proteins which yielded the highest
levels of CAT conversion were pcDNA3-PA, 0.5 mg; pcDNA3-
PB1, 0.5 mg; pcDNA3-PB2, 0.5 mg; pcDNA3-NP, 1 mg; and
HABCAT RNA, 1 mg. No CAT activity was detected if the
HABCAT RNA alone was transfected, or if any one of the
four plasmids was omitted (data not shown). This is consistent
with the observation by Jambrina et al. (13) that NP and the
three P proteins are the minimum set of influenza B virus
proteins required for the expression of a model RNA.
N-terminal deletions in influenza B virus NP do not affect
the expression of HABCAT RNA. To determine if the N-ter-
minal extension plays a role in the ability of NP to support the
expression of a model influenza B virus RNA, 293 cells were
transfected with HABCAT RNA, the polymerase clones, and
plasmids for the expression of either NP, NPD51, or NPD69.
Wild-type levels of CAT conversion were observed when
NPD51 or NPD69 was supplied (Fig. 5). We also obtained
approximately equal levels of CAT conversion when pcDNA3-
NP, pcDNA3-NPD51, and pcDNA3-NPD69 were supplied at a
range of suboptimal amounts while keeping the concentrations
of the P clones and HABCAT RNA the same (data not
shown). This indicates that the N-terminal extension of influ-
enza B virus NP is not involved in the binding of NP to the
RNA or the initiation and elongation of transcription.
The influenza B virus plasmid-based system can be used to
study the replication of viral RNA. It has been reported that
cells which supply the influenza A virus NP and P proteins in
FIG. 4. Expression of HABCAT RNA in cells supplying PA, PB1, PB2, and
NP in trans. Approximately 106 293 cells in 35-mm-diameter dishes were trans-
fected with 0.5 mg of pcDNA3-PA, 0.5 mg of pcDNA3-PB1, 0.5 mg of pcDNA3-
PB2, and 1 mg of pcDNA3-NP by using 20 mg of Lipofectamine (GIBCO/BRL)
in serum-free Eagle’s minimal essential medium (EMEM) according to the
manufacturer’s instructions. At time zero and at 3, 6, 9, 12, and 24 h after
transfection of the plasmids a separate mixture of 1 mg of HABCAT RNA and
20 mg of Lipofectamine was added. HABCAT RNA was synthesized in vitro in
a 25-ml reaction mixture containing 1 mg of HgaI-linearized pT3HABCAT (4), 40
mM Tris-HCl (pH 8.0), 50 mM NaCl, 8 mM MgCl2, 10 mM dithiothreitol, 2 mM
spermidine, the four dNTPs (1 mM each), 30 U of human placental RNase
inhibitor, and 50 U of T3 RNA polymerase. After incubation at 37°C for 1 h, 2
U of RQ1 RNase-free DNase (Promega) was added to remove the template and
the RNA was extracted with phenol-chloroform and precipitated with ethanol.
After 24 h at 37°C the cells were supplemented with 1 ml of EMEM containing
10% heat-inactivated fetal calf serum. Forty-eight hours posttransfection the
cells were harvested into 100 ml of 250 mM Tris-HCl (pH 7.5) and lysed by
freezing and thawing three times. Lysates (50 ml) were then processed for the
detection of CAT as described elsewhere (21).
FIG. 5. Expression of HABCAT RNA is not affected by the removal of the
N-terminal extension of influenza B virus NP. 293 cells were transfected with 0.5
mg of pcDNA3-PA, 0.5 mg of pcDNA3-PB1, 0.5 mg of pcDNA3-PB2, and 1 mg
of either pcDNA3-NP, pcDNA3-NPD51, pcDNA3-NPD69, pHMG-NP, or
pcDNA3 by using 20 mg of Lipofectamine. Immediately after, a separate mixture
of 1 mg of HABCAT RNA and 20 mg of Lipofectamine was added.
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trans are capable of synthesizing viral RNA from a transfected
model cRNA template (12). In order to determine if the
cloned influenza B virus NP and P proteins can synthesize viral
RNA, 293 cells were cotransfected with plasmids for the ex-
pression of the NP and P proteins and a synthetic RNA cor-
responding to the cRNA intermediate of HABCAT RNA rep-
lication. We were able to detect CAT activity in the transfected
cells, at levels comparable to those achieved with negative-
sense HABCAT RNA (Fig. 6). A low level of CAT activity
could be detected if the HABCAT cRNA was cotransfected
into cells with pcDNA3 in place of the NP and P plasmids,
indicating that the RNA can be weakly translated. The ability
to detect elevated levels of CAT in the cells supplying NP and
P proteins suggests that viral RNA was synthesized from the
input RNA and was subsequently transcribed to give mRNA.
We observed that deletion of the N-terminal 51 or 69 residues
of the NP did not affect its ability to support the replication of
the transfected model RNA in this system (Fig. 6).
Influenza B virus NP cannot be functionally replaced by
type A virus NP. We also investigated if the influenza A virus
NP is capable of replacing the type B virus NP in the plasmid-
based system by supplying pHMG-NP in place of pcDNA3-NP.
Plasmid pHMG-NP encodes the A/PR/8/34 NP and has been
used to drive the expression of an influenza A virus model
RNA in the plasmid-based system described by Pleschka et al.
(30). No CAT activity was detected in the transfection by using
pHMG-NP, the influenza B virus P clones, and either HAB-
CAT RNA (Fig. 5) or the cRNA intermediate of HABCAT
replication (Fig. 6), indicating that the influenza A virus NP
cannot form functional RNP complexes with the B virus poly-
merase proteins and a model influenza B virus RNA. It is
known, however, that the four influenza A virus core proteins
can form functional RNPs with a model influenza B virus
RNA, whether this complex is reconstituted in vitro (19, 24) or
in vivo (13).
The finding that type A and B virus NPs are not interchange-
able is consistent with the observations of Jambrina et al. (13)
and indicates that there are type-specific interactions between
NP and the P proteins that are essential for the expression and
replication of the virus genome. This notion is supported by
the finding that natural reassortment of the NP and P genes of
influenza A and B viruses is not observed (14, 23). We consider
this surprising, as the sequences of the type A and B virus NPs
have 37.7% identity and 76.2% similarity over a 496-amino-
acid overlap. It seems unlikely that the N-terminal extension of
influenza B virus NP is involved in type-specific interactions
with the type B virus P proteins, since its removal does not
affect the activity of the RNP complex.
It is possible that the N-terminal extension of type B virus
NP has a role in the specific incorporation of vRNPs into
influenza B virus particles. It has been reported that, while type
A and B virus NPs may exist in the same RNP complex in vivo,
these phenotypically mixed forms are not incorporated into
virions (33). Since the NPs of type A and B viruses differ most
at their N termini, the N-terminal extension may be involved in
the selection of RNPs containing only type B virus NP.
The type-specific nature of the interaction of NP with the P
proteins may be influenced by differences in the posttransla-
tional processing of the influenza A and B virus NPs. It is
known that influenza A virus NP is modified by phosphoryla-
tion (2, 16) and by proteolytic cleavage (36). The extent of
these modifications varies with the virus strain, the cell line on
which the virus is grown, and the phase of the replication cycle
(16, 36, 37). The type B virus NP is also proteolytically cleaved,
but in a manner distinct from that in which influenza A virus
NPs are cleaved (37).
Posttranslational processing of the NP may also modulate
the nuclear import and export of the protein. There is evidence
that the nucleocytoplasmic shuttling of the influenza A virus
NP may be controlled by phosphorylation, since protein kinase
inhibitor H7 causes the redistribution of NP (expressed in the
absence of other virus proteins) from the cytosol to the nucleus
(25). So far nothing is known of the sites and extent of phos-
phorylation of type B virus NP, or whether the proteolytic
processing of NP is relevant to its activity. The plasmid-based
system described here may prove useful in assessing the im-
portance of posttranslational modifications of the NP, and in
identifying those regions of the influenza B virus NP that are
involved in type-specific interactions with the P proteins.
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